Figure 1. Multiplex PCR in clinical diagnostics — from a single swab specimen to differentiated pathogen results in one reaction.

Clinical diagnosis often begins with a simple question: what is causing the patient’s symptoms?

That question gets harder to answer when different pathogens produce nearly identical clinical pictures. It’s the same challenge this series opened with — overlapping respiratory viruses that a clinician can’t reliably tell apart by symptoms alone — and it just played out again in a very different part of the body.

On July 9, 2026, FDA issued an Emergency Use Authorization to Seegene USA for the Allplex HSV-1&2/VZV/MPXV Assay — a multiplex real-time PCR test that simultaneously detects and differentiates herpes simplex virus type 1, herpes simplex virus type 2, varicella-zoster virus, and mpox virus from a single specimen. FDA describes it as the first multiplex PCR test authorized in the US specifically to support differential diagnosis of the viral causes of ulcerative skin lesions — conditions that can look clinically identical despite having entirely different causes and clinical implications.

It’s a narrow authorization, for a specific clinical scenario. But it’s also a useful, concrete case study in where multiplex molecular testing is headed — and what that means for the reagents underneath it.

What Is Multiplex PCR?

Traditional singleplex PCR detects one primary target per reaction. When several pathogens are plausible causes of a patient’s symptoms, a lab running singleplex assays needs to run — and a patient needs to wait for — multiple separate tests.

Multiplex PCR combines multiple primer and probe sets into a single reaction, allowing several targets to be amplified and detected simultaneously. That’s valuable anywhere different pathogens produce overlapping symptoms — which describes a lot of infectious disease diagnosis, not just respiratory illness.

But multiplex PCR isn’t simply “add more primers to the tube.” Every additional target increases the complexity of assay optimization: primer interactions, amplification efficiency, nonspecific amplification, fluorescence signal management, and reaction chemistry all have to be balanced together rather than tuned one target at a time — a scaling challenge documented in the multiplex PCR literature since the technique’s earliest protocols.

What the Allplex Authorization Actually Means

HSV-1, HSV-2, VZV, and mpox virus can all produce vesicular, pustular, or ulcerative skin lesions that look alike to the eye. Testing for only one pathogen at a time — the traditional approach — risks missing the others entirely when the causative virus isn’t the one initially suspected. The Allplex assay lets clinicians evaluate all four possibilities from one specimen instead of guessing which single test to order first.

One specimen. Multiple targets. A broader molecular view of the potential cause.

Figure 3. How the Allplex assay maps four clinically overlapping pathogens to one specimen and one differential diagnosis.

Two things are worth being precise about here, because overstating a regulatory milestone is its own kind of misinformation:

●       An EUA is not full FDA approval. Emergency Use Authorization is a specific regulatory mechanism, issued under Section 564 of the FD&C Act, tied to a declared public health emergency — in this case, the HHS mpox declaration originally made in September 2022. It isn’t FDA establishing multiplex PCR as a universal clinical standard, and it doesn’t carry the same regulatory weight as a cleared or approved diagnostic.

●       What it does signal is real. Regulatory milestones like this one draw attention to where clinical need is outpacing single-target testing, and this authorization is a clear marker of a broader trend already visible across molecular diagnostics: multi-pathogen panels increasingly replacing single-target tests as the default first step in differential diagnosis.

How Multiplex PCR Changes the Clinical Workflow

Figure 2. Singleplex versus multiplex PCR workflow — fewer testing steps, but more that has to be optimized in the reaction itself.

A traditional workflow runs sequentially: symptoms point to a suspected pathogen, a single test is ordered, a result comes back, and if it’s negative, testing continues down the list of possibilities. Multiplex PCR compresses that into: symptoms, sample collection, one multiplex reaction, multiple pathogen results, clinical decision.

That compression doesn’t make assay development easier — it moves the complexity earlier. The trade-off shows up clearly when the two approaches are compared directly:

The pattern holds regardless of which pathogens are on the panel: multiplex PCR can simplify the diagnostic workflow while increasing the complexity of assay development behind it.

What Makes Multiplex PCR Technically Challenging

Four things determine whether a multiplex panel actually performs once it leaves the development bench:

Figure 4. Six variables that have to be optimized together in multiplex PCR assay development — more targets means more of each.

Primer and probe compatibility. More targets means more opportunities for primer-primer interactions, primer-dimer formation, cross-reactivity, and competition between targets — all of which can degrade both sensitivity and specificity if the full reaction system isn’t optimized together, not component by component.

Balanced amplification across targets. Different targets amplify differently depending on GC content, amplicon length, primer properties, target abundance, and template structure. A strong signal from one target shouldn’t come at the expense of detecting another — which is precisely where polymerase selection and reaction chemistry matter most. HZYMES offers PCR enzymes and master mixes designed for complex multiplex reaction conditions, supporting controlled and consistent amplification across challenging assay designs.

Sensitivity and specificity under multiplex conditions. With several primer and probe sets present simultaneously, controlling unwanted amplification during reaction setup becomes more important, not less — the molecular lock concept covered earlier in this series scales directly with target count. HZYMES’s FS Hot Start Plus Taq DNA Polymerase (Antibody-Modified), HMD0221, provides fast hot-start activation without giving up the specificity a crowded multiplex reaction depends on.

Fluorescence channel management. Multiplex qPCR assigns different targets to different fluorescent channels, which means signal separation, baseline interpretation, and target-specific probe performance all need to be coordinated alongside the amplification chemistry itself.

The HZYMES Portfolio for Multiplex PCR Development

Multiplex assay performance depends on the interaction of several components, not one hero reagent. HZYMES’s portfolio spans the categories that matter most across a multiplex development project:

Figure 5. HZYMES's core PCR components — enzymes, premixes, and technical services — spanning a multiplex assay development project.

Where Multiplex PCR Is Headed

Figure 6. The Allplex authorization covers skin lesion pathogens, but the same logic — multiple possible causes, one integrated test — is already reshaping testing across other syndromic categories, respiratory panels included.

The skin-lesion use case is a clean illustration of the pattern, but it’s far from the only place it applies. The same principle — multiple possible causes, multiple molecular targets, one integrated workflow — is already active across respiratory pathogen panels, gastrointestinal pathogen panels, sexually transmitted infection testing, central nervous system infection testing, and skin and soft tissue infection testing.

The broader trajectory looks like this: single-pathogen testing gave way to multiplex panels, and multiplex panels are giving way to more integrated molecular diagnostics generally. Each step up in target count raises the bar for polymerase specificity, balanced amplification, reaction compatibility, reagent consistency, workflow stability, and scalable manufacturing — which is exactly the set of engineering problems this series has walked through, one at a time, starting from a multiplex respiratory panel sitting in a tube.

Closing the Loop

This series started with a scene: US respiratory testing season opening, and multiplex panels facing down a “crossfire” of co-circulating pathogens. From there, we traced that pressure back through the supply chain feeding those panels, down into the enzyme chemistry that makes multiplexing work at all, into the specific antibody engineering HZYMES built to solve it, out through the global logistics of getting a stable reagent from manufacturer to lab bench — and now, out to the regulatory landscape validating multiplex PCR as the direction clinical diagnostics is actually moving.

The throughline across all six articles is the same: a multiplex panel is only as reliable as the reagent chemistry underneath it. Choosing the right combination of PCR master mix and core enzymes is what turns a promising panel design into one that performs consistently — in validation, in production, and in the clinic.

References

1. Federal Register. Authorization of Emergency Use of an In Vitro Diagnostic Device in Response to an Outbreak of Mpox; Availability. Docket No. FDA–2026–N–7956. Published August 6, 2026. Official FDA notice confirming the July 9, 2026 EUA issuance to Seegene USA for the Allplex HSV-1&2/VZV/MPXV Assay. https://www.federalregister.gov/documents/2026/08/06/2026-15964/authorization-of-emergency-use-of-an-in-vitro-diagnostic-device-in-response-to-an-outbreak-of-mpox

2. Seegene, Inc. Seegene USA Receives FDA Emergency Use Authorization for Multiplex PCR Assay, Advancing Differential Diagnosis of HSV-1&2, VZV, and Monkeypox Virus for Ulcerative Skin Lesions. July 21, 2026.

  https://www.biospace.com/press-releases/seegene-usa-receives-fda-emergency-use-authorization-for-multiplex-pcr-assay-advancing-differential-diagnosis-of-hsv-1-2-vzv-and-monkeypox-virus-for-ulcerative-skin-lesions

3. CAP TODAY. Seegene USA gets EUA for HSV, VZV, mpox assay. July 23, 2026. https://www.captodayonline.com/seegene-usa-gets-eua-for-hsv-vzv-mpox-assay/

4. Henegariu O, Heerema NA, Dlouhy SR, Vance GH, Vogt PH. Multiplex PCR: critical parameters and step-by-step protocol. BioTechniques. 1997;23(3):504–511. https://doi.org/10.2144/97233rr01

Product performance and specification data reflects HZYMES internal validation testing. Full technical data sheets are available on request.

FAQ

What did FDA authorize for multiplex PCR testing in 2026?

On July 9, 2026, FDA issued an Emergency Use Authorization to Seegene USA for the Allplex HSV-1&2/VZV/MPXV Assay, a multiplex real-time PCR test that simultaneously detects and differentiates HSV-1, HSV-2, varicella-zoster virus, and mpox virus from ulcerative skin lesion specimens.

Is an FDA Emergency Use Authorization the same as full FDA approval?

No. An EUA is a distinct regulatory mechanism issued under Section 564 of the FD&C Act during a declared public health emergency. It authorizes emergency use of a diagnostic but does not carry the same regulatory status as full FDA clearance or approval.

Why is multiplex PCR more technically demanding than singleplex PCR?

Every additional target in a multiplex reaction increases the potential for primer-primer interactions, primer-dimer formation, and uneven amplification efficiency across targets, requiring the full reaction system — not each component individually — to be optimized together.

What diagnostic areas is multiplex PCR expanding into?

Beyond respiratory and skin-lesion panels, multiplex PCR is increasingly used in gastrointestinal pathogen panels, sexually transmitted infection testing, and central nervous system infection testing — anywhere multiple possible pathogens can produce similar clinical presentations.

What should assay developers look for in PCR reagents for multiplex panels?

Polymerase specificity under multiplex load, balanced amplification across all targets, reagent consistency from lot to lot, and — for panels intended for broad or decentralized distribution — stability formats such as lyophilization-ready formulations.